Evidence map›Paper›PMID 38966313›Full record

ArticleChina CDC weekly2024

The COVID-19 Vaccines Evaluation Program: Implementation, Management, and Experiences, 2021-2023.

Tingting Yan, Hui Zheng, Mingshuang Li, Chao Ma, Xuanyi Wang, Xiaoqi Wang, Zhenjun Li, Yuansheng Chen, Wenshang Hu, Lance Rodewald and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in China CDC weekly, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tingting YanNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID). National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Hui ZhengNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID). National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Mingshuang LiNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID). National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Chao MaNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID). National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Xuanyi WangInstitutes of Biomedical Sciences, Fudan University, Shanghai, China.
Xiaoqi WangOffice of International Cooperation, Chinese Center for Disease Control and Prevention, Beijing, China.
Zhenjun LiOffice of Science and Technology, Chinese Center for Disease Control and Prevention, Beijing, China.
Yuansheng ChenOffice of Science and Technology, Chinese Center for Disease Control and Prevention, Beijing, China.
Wenshang HuOffice of Finance, Chinese Center for Disease Control and Prevention, Beijing, China.
Lance RodewaldNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID). National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Zhijie AnNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID). National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Zundong YinNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID). National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Zijian FengChinese Preventive Medicine Association, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2021, China's domestically produced coronavirus disease 2019 (COVID-19) vaccines received approval from regulatory bodies and were administered worldwide. Due to a low number of infections within China during that period, it became imperative to evaluate the vaccines' real-world effectiveness through international studies. To facilitate this, China CDC launched the COVID-19 Vaccines Evaluation Program (COVEP). This program formed research collaboration agreements with health institutes across five World Health Organization regions, addressing key questions about vaccine performance through ten cooperative agreements. The findings from COVEP projects reinforced confidence, both domestically and globally, in the effectiveness of the vaccines produced in China. Moreover, the outcomes observed internationally were frequently mirrored by later studies conducted within China. COVEP thus pioneered a novel approach for fostering cross-national research collaborations, addressing significant public health issues and exemplifying a framework for international cooperation. This approach is in line with the strategic objectives and other development efforts of China CDC's national disease control and prevention initiatives.

Indexed as

experiencesimplementationmanagementthe COVID-19 Vaccines Evaluation Program (COVEP)

Identifiers

PMID38966313
PMCPMC11219299

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.